Collectively, our data suggest that HL-RG may treat RCC by modulating TGFB1/CCND1/MMP9/ERBB2/CAT/PPARα networks via NF-κB, PI3K/AKT, and TGF-β pathways. Here, NFKB1 is linked to renal cell carcinoma.